增加线粒体能量代谢的抗抑郁药可能升高治疗中出现躁狂的风险
该回顾性研究基于双相障碍临床表型队列,将既往暴露的抗抑郁药按临床前证据分为增加(Mito+)或降低(Mito-)线粒体电子传递链活性两类,比较治疗中出现躁狂(TEM)的发生率。在调整年龄、性别和双相亚型后,Mito+抗抑郁药暴露者的TEM+频率高于Mito-暴露者(24.7% vs 13.5%,OR=2.21,p=0.000009)。提示可基于线粒体能量代谢重新审视抗抑郁药分类。
要点
- Mito+抗抑郁药暴露者TEM+频率为24.7%,高于Mito-的13.5%。
- 调整年龄、性别和双相亚型后,Mito+与TEM风险升高相关(OR=2.21,p=0.000009)。
- 作者建议未来开展针对具体抗抑郁药与线粒体活性的前瞻性临床研究。
核心结论
- 回顾性数据提示,增加线粒体能量代谢的抗抑郁药可能升高双相障碍患者治疗中出现躁狂的风险。
研究设计与样本
- 回顾性研究,纳入已临床表型为TEM+(n=176)或TEM-(n=516)的双相障碍参与者,并按既往暴露的抗抑郁药分为Mito+(n=600)或Mito-(n=289)组。
- 采用广义估计方程比较Mito+与Mito-抗抑郁药的TEM+发生率,并调整性别、入组生物样本库时年龄及双相障碍类型(BD-I/分裂情感性 vs BD-II)。
- 共分析692名受试者(62.7%女性,91.4%白人,平均年龄43.0±14.0岁),其中TEM+ 176例(25.3%),TEM- 516例(74.7%)。
主要发现
- 调整年龄、性别和双相亚型后,Mito+抗抑郁药暴露者的TEM+频率为24.7%,高于Mito-暴露者的13.5%(OR=2.21;p=0.000009)。
临床怎么用
- 对双相障碍患者处方抗抑郁药时,可考虑药物对线粒体能量代谢的影响,以评估治疗中出现躁狂的风险。
局限性
- 本研究为初步回顾性数据,尚需前瞻性临床研究验证具体抗抑郁药与线粒体活性的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Preclinical evidence suggests that antidepressants (ADs) may differentially influence mitochondrial energetics. This study was conducted to investigate the relationship between mitochondrial function and illness vulnerability in bipolar disorder (BD), specifically risk of treatment-emergent mania (TEM). Participants with BD already clinically phenotyped as TEM+ (n = 176) or TEM- (n = 516) were further classified whether the TEM associated AD, based on preclinical studies, increased (Mito+, n = 600) or decreased (Mito-, n = 289) mitochondrial electron transport chain (ETC) activity. Comparison of TEM+ rates between Mito+ and Mito- ADs was performed using generalized estimating equations to account for participants exposed to multiple ADs while adjusting for sex, age at time of enrollment into the biobank and BD type (BD-I/schizoaffective vs. BD-II). A total of 692 subjects (62.7% female, 91.4% White, mean age 43.0 ± 14.0 years) including 176 cases (25.3%) of TEM+ and 516 cases (74.7%) of TEM- with previous exposure to Mito+ and/or Mito- antidepressants were identified. Adjusting for age, sex and BD subtype, TEM+ was more frequent with antidepressants that increased (24.7%), versus decreased (13.5%) mitochondrial energetics (OR = 2.21; p = 0.000009). Our preliminary retrospective data suggests there may be merit in reconceptualizing AD classification, not solely based on monoaminergic conventional drug mechanism of action, but additionally based on mitochondrial energetics. Future prospective clinical studies on specific antidepressants and mitochondrial activity are encouraged. Recognizing pharmacogenomic investigation of drug response may extend or overlap to genomics of disease risk, future studies should investigate potential interactions between mitochondrial mechanisms of disease risk and drug response.
引用
- Gardea-Resendez M, Coombes BJ, Veldic M, et al. Antidepressants that increase mitochondrial energetics may elevate risk of treatment-emergent mania. Mol Psychiatry. 2022. PMID: 36513812. doi:10.1038/s41380-022-01888-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。